[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Kuppermann M, Melnikow J, Slee C, Tancredi DJ, Kulasingam S, Birch S, Helms LJ, Bayoumi AM, Sawaya GF: Preferences for surveillance strategies for women treated for high-grade precancerous cervical lesions. Gynecol Oncol; 2010 Aug 1;118(2):108-15
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preferences for surveillance strategies for women treated for high-grade precancerous cervical lesions.
  • OBJECTIVES: Data are lacking on how women view alternative approaches to surveillance for cervical cancer after treatment of high-grade cervical intraepithelial neoplasia.
  • We measured and compared patient preferences (utilities) for scenarios with varying surveillance strategies and outcomes to inform guidelines and cost-effectiveness analyses of post-treatment surveillance options.
  • Participation consisted of one face-to-face interview, during which utilities for 11 different surveillance scenarios and their associated outcomes were elicited using the time tradeoff metric.
  • Mean utilities ranged from 0.989 (undergoing only a Pap test, receiving normal results) to 0.666 (invasive cervical cancer treated with radical hysterectomy or radiation and chemotherapy).

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • [Cites] J Fam Pract. 2002 Oct;51(10):849-55 [12401153.001]
  • [Cites] Obstet Gynecol. 2009 Dec;114(6):1409-20 [20134296.001]
  • [Cites] Prenat Diagn. 2004 Jun;24(6):424-9 [15229840.001]
  • [Cites] Health Serv Res. 1972 Summer;7(2):118-33 [5044699.001]
  • [Cites] J Health Econ. 1986 Mar;5(1):1-30 [10311607.001]
  • [Cites] Health Psychol. 1991;10(4):259-67 [1915212.001]
  • [Cites] Cancer Causes Control. 1997 Sep;8(5):755-63 [9328198.001]
  • [Cites] J Clin Epidemiol. 1998 Nov;51(11):1171-8 [9817135.001]
  • [Cites] COPD. 2005 Mar;2(1):91-7 [17136968.001]
  • [Cites] Med Decis Making. 2007 Jul-Aug;27(4):414-22 [17585005.001]
  • [Cites] Obstet Gynecol. 2007 Sep;110(3):633-42 [17766611.001]
  • [Cites] J Low Genit Tract Dis. 2007 Oct;11(4):223-39 [17917567.001]
  • [Cites] Health Econ. 2008 May;17(5):593-605 [17764095.001]
  • [Cites] Obstet Gynecol. 2008 Dec;112(6):1419-44 [19037054.001]
  • [Cites] Gynecol Oncol. 2009 May;113(2):216-20 [19217148.001]
  • [Cites] Lancet Oncol. 2009 Jul;10(7):672-82 [19540162.001]
  • [Cites] Cancer Causes Control. 2009 Sep;20(7):1129-38 [19253025.001]
  • [Cites] Sex Transm Infect. 2009 Dec;85(7):508-13 [19703844.001]
  • [Cites] Health Econ. 2003 Oct;12(10):879-84 [14508872.001]
  • (PMID = 20553960.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA109142-01A1; United States / NCI NIH HHS / CA / P30 CA093373; United States / NCI NIH HHS / CA / R01 CA109142; United States / NCI NIH HHS / CA / R01 CA109142-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS210073; NLM/ PMC2926130
  •  go-up   go-down


2. Diaz-Arrastia C, Arany I, Robazetti SC, Dinh TV, Gatalica Z, Tyring SK, Hannigan E: Clinical and molecular responses in high-grade intraepithelial neoplasia treated with topical imiquimod 5%. Clin Cancer Res; 2001 Oct;7(10):3031-3
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and molecular responses in high-grade intraepithelial neoplasia treated with topical imiquimod 5%.
  • OBJECTIVE: To assess the clinical and molecular response of patients with recurrent high-grade vulvar, vaginal, or cervical intraepithelial neoplasia treated with topical 1-2(2-methylpropyl)-1H-imidazo [4,5-c] quinolin-4-amine (imiquimod) cream 5%, an immune response modifier with known efficacy in the treatment of external genital warts.
  • METHODS: This is the first case series in the peer-reviewed literature reporting the use of imiquimod in high-grade intraepithelial neoplasia of the lower genital tract.
  • Eight patients with high-grade intraepithelial neoplasia were treated with imiquimod in the gynecological oncology clinic and the HIV gynecology clinic at The University of Texas Medical Branch at Galveston.
  • Frozen biopsies were available for RNA extraction on four patients before and after therapy.
  • RESULTS: Of the patients treated, four had complete responses, two had partial responses, one progressed, and one did not tolerate the therapy.
  • 2',5'-Oligoadenylate synthetase RNA expression showed an increased trend after therapy.
  • CONCLUSIONS: These results obtained in this small and heterogeneous group merit further study in the use of topical 5% imiquimod use in the treatment of intraepithelial neoplasia.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Cervical Intraepithelial Neoplasia / drug therapy. Genital Neoplasms, Female / drug therapy
  • [MeSH-minor] 2',5'-Oligoadenylate Synthetase / genetics. Administration, Topical. Adult. Female. Follow-Up Studies. Gene Expression Regulation, Enzymologic / drug effects. Gene Expression Regulation, Neoplastic / drug effects. Humans. Middle Aged. Ointments. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Time Factors. Treatment Outcome. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / genetics. Vaginal Neoplasms / drug therapy. Vaginal Neoplasms / genetics. Vulvar Neoplasms / drug therapy. Vulvar Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11595691.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Ointments; 0 / RNA, Neoplasm; 99011-02-6 / imiquimod; EC 2.7.7.- / 2',5'-Oligoadenylate Synthetase
  •  go-up   go-down


3. Keefe KA, Schell MJ, Brewer C, McHale M, Brewster W, Chapman JA, Rose GS, McMeeken DS, Lagerberg W, Peng YM, Wilczynski SP, Anton-Culver H, Meyskens FL, Berman ML: A randomized, double blind, Phase III trial using oral beta-carotene supplementation for women with high-grade cervical intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev; 2001 Oct;10(10):1029-35
Hazardous Substances Data Bank. BETA-CAROTENE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized, double blind, Phase III trial using oral beta-carotene supplementation for women with high-grade cervical intraepithelial neoplasia.
  • To evaluate the effect of daily beta-carotene (30 mg) versus placebo over a 2-year period on cervical intraepithelial neoplasia (CIN) 2 and 3 lesions.
  • Cervical biopsies were performed before treatment and after 6 and 24 months to evaluate response.
  • Persistence of or progression to CIN 3 resulted in removal from the study, whereas treatment continued for 2 years on all others.
  • The presence and type of HPV was determined by PCR.
  • Mantel-Haenszel chi(2) test was used to analyze response to treatment.
  • Fisher's exact test was used to determine the effect of HPV and CIN grade on response Wilcoxon's rank-sum tests were used to compare micronutrient levels between groups.
  • The overall regression rate (32%) was similar between treatment arms and when stratified for CIN grade.
  • HPV-positive lesions were subdivided into indeterminate-, low-, and high-risk categories; the response rate was highest for women with no HPV detected (61%), lower for indeterminate/low-risk (30%), and lowest for high-risk (18%; P =.001).
  • In conclusion, beta-carotene does not enhance the regression of high-grade CIN, especially in HPV-positive subjects.
  • [MeSH-major] Antioxidants / administration & dosage. Cervical Intraepithelial Neoplasia / drug therapy. Uterine Cervical Neoplasms / drug therapy. beta Carotene / administration & dosage
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Biopsy, Needle. Dietary Supplements. Double-Blind Method. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Logistic Models. Long-Term Care. Middle Aged. Probability. Reference Values. Severity of Illness Index. Treatment Outcome. Vaginal Smears


Advertisement
4. Haidopoulos D, Diakomanolis E, Rodolakis A, Voulgaris Z, Vlachos G, Intsaklis A: Can local application of imiquimod cream be an alternative mode of therapy for patients with high-grade intraepithelial lesions of the vagina? Int J Gynecol Cancer; 2005 Sep-Oct;15(5):898-902
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can local application of imiquimod cream be an alternative mode of therapy for patients with high-grade intraepithelial lesions of the vagina?
  • The aim of the present study was to assess the local application of imiquimod cream 5% as an alternative mode of therapy for high-grade vaginal intraepithelial neoplasia (VAIN 2/3).
  • Positive human papillomavirus (HPV) patients with multifocal high-grade VAIN (2/3) not involving the vaginal vault in hysterectomized patients took part in this study.
  • The treatment consisted of vaginal application of the cream under colposcopic guidance.
  • Following management, biopsies were obtained from the previously recorded lesions. p53 expression was recorded prior and after therapy.
  • Seven patients with VAIN 2/3 took part in this study.
  • Six patients (86%) were positive for high-risk HPV type while three (43%) women who were positive for p53 nuclei prior to therapy were found to be negative following treatment.
  • After treatment, 86% of the patients were found to have either HPV infection or low-grade VAIN.
  • During follow-up, two patients (28.5%) were managed by vaginectomy, one for persistent and one for recurrent high-grade VAIN.
  • Currently, from the five patients that are followed, three have simple HPV infection and two, VAIN 1.
  • Imiquimod cream 5% might represent an alternative although not permanent method of management in young, HPV-positive women with multifocal high-grade lesions of the vagina (VAIN 2/3).
  • [MeSH-major] Aminoquinolines / administration & dosage. Aminoquinolines / therapeutic use. Epithelial Cells / pathology. Vaginal Neoplasms / drug therapy. Vaginal Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Humans. Middle Aged. Vaginal Creams, Foams, and Jellies / administration & dosage. Vaginal Creams, Foams, and Jellies / therapeutic use

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Imiquimod .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16174242.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Vaginal Creams, Foams, and Jellies; 99011-02-6 / imiquimod
  •  go-up   go-down


5. Indraccolo U, Del Frate E, Cenci S, Ubertosi M, Donati Sarti R, Donati Sarti C, Baldoni A: [Vaginal intraepithelial neoplasia and human papillomavirus infection: a report of 75 cases]. Minerva Ginecol; 2006 Apr;58(2):101-8
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Vaginal intraepithelial neoplasia and human papillomavirus infection: a report of 75 cases].
  • [Transliterated title] La neoplasia intraepiteliale vaginale e l'infezione da virus del papilloma umano. Un resoconto di 75 casi.
  • AIM: Vaginal intraepithelial neoplasia (VaIN) is an uncommon and poorly understood disease.
  • Risk factors other than human papillomavirus (HPV) infection could be linked to the onset and evolution of some VaIN.
  • METHODS: In this paper, the results achieved from the analysis of 75 patients with VaIN are reported.
  • From these cases, women with HIV, previous hysterectomy, autoimmune diseases and radio- and chemotherapy have been excluded.
  • They have been examined after a distinction between grade and association with coilocytosis.
  • VaIN preferential localization, mean age of patients and manifestation pattern after vaginal colposcopy have then been examined.
  • RESULTS: Although the population size cannot allow evidences, it seems that VaIN with coilocytosis and VaIN I without coilocytosis have preferential localization in the upper third of the vagina.
  • It does not appear that mean age of patients for each grade of VaIN differs significativly, both associated and not associated with coilocytosis.
  • Finally, after vaginal colposcopy, the pattern of VaIN for each grade is absolutely not typical, and it seems that white thin epithelium or negative Lugol area are usually the manifestation of high grades of VaIN too.
  • CONCLUSIONS: These results, if confirmed, could mean that VaIN due to HPV may have a different natural history relating to the site of localization in the vagina and, moreover, that also VaIN of high grade could appear with an innocent vaginal pattern.
  • [MeSH-major] Carcinoma in Situ / complications. Carcinoma in Situ / pathology. Papillomaviridae. Papillomavirus Infections / complications. Papillomavirus Infections / pathology. Vaginal Neoplasms / complications. Vaginal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16582866.001).
  • [ISSN] 0026-4784
  • [Journal-full-title] Minerva ginecologica
  • [ISO-abbreviation] Minerva Ginecol
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


6. Lin H, Huang EY, Chang HY, ChangChien CC: Therapeutic effect of topical applications of trichloroacetic acid for vaginal intraepithelial neoplasia after hysterectomy. Jpn J Clin Oncol; 2005 Nov;35(11):651-4
Hazardous Substances Data Bank. TRICHLOROACETIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic effect of topical applications of trichloroacetic acid for vaginal intraepithelial neoplasia after hysterectomy.
  • OBJECTIVE: We attempted to evaluate the therapeutic effect of trichloroacetic acid (TCA) for vaginal intraepithelial neoplasia (VaIN) after hysterectomy and to identify factors affecting persistence/recurrence.
  • METHODS: Twenty-eight post-hysterectomy patients with various grades of VaIN were enrolled in this study between January 2001 and December 2003.
  • RESULTS: In 20 of 28 patients (71.4%) VaIN went into remission.
  • Treatment success was observed in all 11 patients with VaIN I, whereas only 9 out of 17 patients (53%) with VaIN II/III went into remission (P = 0.009).
  • Severity of VaIN was the only significant independent predictor of persistence/recurrence (odds ratio = 3.5; 95% confidence interval = 1.1, 11.6; P = 0.038).
  • The treatment was well tolerated with no major side effects.
  • CONCLUSIONS: Based on our findings, 50% TCA was a potential agent with minimal side effects for low-grade VaIN.
  • However, as for high-grade lesions, further investigation with different TCA concentration is compelling.
  • [MeSH-major] Carcinoma in Situ / drug therapy. Hysterectomy. Trichloroacetic Acid / therapeutic use. Vaginal Neoplasms / drug therapy
  • [MeSH-minor] Administration, Topical. Adult. Aged. Drug Administration Schedule. Female. Humans. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Postoperative Care

  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16275678.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5V2JDO056X / Trichloroacetic Acid
  •  go-up   go-down


7. Diakomanolis E, Haidopoulos D, Stefanidis K: Treatment of high-grade vaginal intraepithelial neoplasia with imiquimod cream. N Engl J Med; 2002 Aug 1;347(5):374
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of high-grade vaginal intraepithelial neoplasia with imiquimod cream.
  • [MeSH-major] Aminoquinolines / administration & dosage. Antineoplastic Agents / administration & dosage. Carcinoma in Situ / drug therapy. Vaginal Neoplasms / drug therapy
  • [MeSH-minor] Adjuvants, Immunologic / administration & dosage. Administration, Intravaginal. Adult. Female. Humans. Middle Aged. Neoplasm Staging. Tumor Suppressor Protein p53 / analysis. Vaginal Creams, Foams, and Jellies

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12151484.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Tumor Suppressor Protein p53; 0 / Vaginal Creams, Foams, and Jellies; 99011-02-6 / imiquimod
  •  go-up   go-down


8. González Sánchez JL, Flores Murrieta G, Chávez Brambila J, Deolarte Manzano JM, Andrade Manzano AF: [Topical 5-fluorouracil for treatment of vaginal intraepithelial neoplasms]. Ginecol Obstet Mex; 2002 May;70:244-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Topical 5-fluorouracil for treatment of vaginal intraepithelial neoplasms].
  • [Transliterated title] 5-fluorouracilo tópico en el tratamiento de la neoplasia intraepitelial vaginal.
  • OBJECTIVE: Our purpose was to determine the effectiveness of 5-fluorouracil (5-FU) in the treatment of vaginal intraepithelial neoplasia (VAIN).
  • MATERIALS AND METHODS: The study was performed in 30 patients with a mean age of 54 years and previous diagnoses from reviewed records and histopathology slides selected from a group of 65 patients with VAIN from 1980 to 1998.
  • Patients received intravaginal treatment with 5-FU, 1.5 g once weekly for 10 weeks and all patients were followed up for at least 2-years.
  • RESULTS: Twenty eight (93%) patients with VAIN had prior or concurrent anogenital squamous neoplasia, including 5 with invasive cervical carcinoma and 23 with cervical intraepithelial neoplasia.
  • In 23 of 30 treated patients (77%), VAIN went into remission after a single treatment; in 3, (10%), it went into remission after two treatment; 3 (10%) had recurrent VAIN 3; and in 1 (3%) it progressed to invasive vaginal cancer.
  • The treatment was well tolerated.
  • CONCLUSIONS: The 5-FU is an option choice for VAIN treatment.
  • Its use should be confined to treating extensive or multifocal high-grade VAIN.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Cervical Intraepithelial Neoplasia / drug therapy. Fluorouracil / therapeutic use. Vaginal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Papanicolaou Test. Papilloma / drug therapy. Papilloma / pathology. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / pathology. Vaginal Smears

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12148464.001).
  • [ISSN] 0300-9041
  • [Journal-full-title] Ginecología y obstetricia de México
  • [ISO-abbreviation] Ginecol Obstet Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


9. Georgiev D, Karag'ozov I, Velev M, Makaveeva V: [Three cases of vaginal adenosis after topical 5-fluorouracil therapy for vaginal HPV-associated lesions]. Akush Ginekol (Sofiia); 2006;45(3):59-61
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Three cases of vaginal adenosis after topical 5-fluorouracil therapy for vaginal HPV-associated lesions].
  • Three cases of vaginal adenosis after topical 5-fluorouracil therapy for vaginal HPV-associated lesions are reported.
  • Three patients with colposcopic, histologic and viral evidences for subclinical papillomavirus infection (in combination with low-grade vaginal intraepithelial neoplasia in of them) are treated with 5-FU.
  • In follow-up control examinations persistent ulcerations were found without regression after applied therapy.
  • By colposcopic and histologic examinations vaginal adenosis was proved without histories of intrautering DES exposure.
  • After the destructive therapy the reported lesions were regressed without appearance of new lesions in follow-up control examinations.
  • The application of 5-fluorouracil has to be used only in cases of recurrent vaginal warts and in cases of high-grade vaginal intraepithelial neoplasia with strict folow-up cytological and colposcopic control examinations.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Fluorouracil / adverse effects. Papillomaviridae / isolation & purification. Papillomavirus Infections / drug therapy. Vaginal Neoplasms / etiology. Vaginitis / drug therapy
  • [MeSH-minor] Administration, Intravaginal. Female. Humans. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • MedlinePlus Health Information. consumer health - Vaginitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16889191.001).
  • [ISSN] 0324-0959
  • [Journal-full-title] Akusherstvo i ginekologii︠a︡
  • [ISO-abbreviation] Akush Ginekol (Sofiia)
  • [Language] bul
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Bulgaria
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


10. Marchesoni D, Driul L, Mozzanega B, Nardelli GB, Parenti A: Intraepithelial G3 adenocarcinoma of the endometrium after tamoxifen treatment. Arch Gynecol Obstet; 2005 Jan;271(1):62-5
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraepithelial G3 adenocarcinoma of the endometrium after tamoxifen treatment.
  • She came to our department because of vaginal bleeding 2 years after the end of tamoxifen treatment.
  • TREATMENT: She underwent hysteroscopy and a D and C.
  • A polypoid endometrium completely filled the uterine cavity and was carefully removed by curettage; histology showed a highly undifferentiated neoplasia with a component of serous adenocarcinoma, which was likely to originate from endometrial polyps.
  • OUTCOME: The patient underwent radical hysterectomy, but no residual tumor was found in the uterus or in the tubes, ovary, or pelvic nodes, in spite of its low differentiation grade and high potential aggressiveness, and even though the patient was already symptomatic.
  • [MeSH-minor] Breast Neoplasms / drug therapy. Breast Neoplasms / surgery. Carcinoma, Ductal / drug therapy. Carcinoma, Ductal / surgery. Chemotherapy, Adjuvant. Dilatation and Curettage. Endometrium / drug effects. Endometrium / pathology. Female. Humans. Hysteroscopy. Mastectomy, Radical. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15290168.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


11. Fehr MK, Hornung R, Degen A, Schwarz VA, Fink D, Haller U, Wyss P: Photodynamic therapy of vulvar and vaginal condyloma and intraepithelial neoplasia using topically applied 5-aminolevulinic acid. Lasers Surg Med; 2002;30(4):273-9
MedlinePlus Health Information. consumer health - Vulvar Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy of vulvar and vaginal condyloma and intraepithelial neoplasia using topically applied 5-aminolevulinic acid.
  • BACKGROUND AND OBJECTIVES: To determine the feasibility of photodynamic therapy (PDT) of vulvar and vaginal condyloma and intraepithelial neoplasia (VIN, VAIN) and to compare PDT results with conventional treatments.
  • STUDY DESIGN/MATERIALS AND METHODS: Thirty-eight patients with vulvar or vaginal intraepithelial neoplasia (VIN) grade II/III (n = 22) or condyloma (n = 16) had 10% 5-aminolevulinic acid (ALA)-gel applied topically.
  • PDT was compared to conventional treatments for condyloma (CO(2) laser evaporation) and for VIN III (laser evaporation, surgical excision).
  • Of the neoplasia patients, none with hyperkeratotic VIN (n = 4) responded, and only one of four with increased pigmentation cleared.
  • Reduced disease-free survival (DFS) was associated with multifocal VIN (P = 0.02, OR 2.17, 95% CI 1.15-4.08), but DFS did not vary with treatment mode.
  • CONCLUSIONS: Although PDT is not equally efficacious for all subgroups, PDT for condyloma and intraepithelial neoplasia appears to be as effective as conventional treatments, but with shorter healing time and excellent cosmetic results.
  • [MeSH-major] Aminolevulinic Acid / administration & dosage. Condylomata Acuminata / drug therapy. Photochemotherapy. Photosensitizing Agents / administration & dosage. Precancerous Conditions / drug therapy. Vaginal Diseases / drug therapy. Vaginal Neoplasms / drug therapy. Vulvar Diseases / drug therapy. Vulvar Neoplasms / drug therapy
  • [MeSH-minor] Administration, Topical. Adolescent. Adult. Aged. Female. Humans. Laser Therapy. Middle Aged

  • MedlinePlus Health Information. consumer health - Genital Warts.
  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • MedlinePlus Health Information. consumer health - Vaginal Diseases.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley-Liss, Inc.
  • (PMID = 11948597.001).
  • [ISSN] 0196-8092
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


12. Shukla S, Bharti AC, Hussain S, Mahata S, Hedau S, Kailash U, Kashyap V, Bhambhani S, Roy M, Batra S, Talwar GP, Das BC: Elimination of high-risk human papillomavirus type HPV16 infection by 'Praneem' polyherbal tablet in women with early cervical intraepithelial lesions. J Cancer Res Clin Oncol; 2009 Dec;135(12):1701-9
Hazardous Substances Data Bank. QUININE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elimination of high-risk human papillomavirus type HPV16 infection by 'Praneem' polyherbal tablet in women with early cervical intraepithelial lesions.
  • PURPOSE: 'Praneem', a polyherbal formulation developed by us, has successfully completed Phase II efficacy study for treatment of abnormal vaginal discharge due to reproductive tract infections that act as co-factors for HPV persistence.
  • In the present study we evaluated potential anti-HPV activity of Praneem in women infected with high risk HPV type 16.
  • METHODS: Twenty women molecularly diagnosed positive for HPV16 infection without or with low grade squamous intraepithelial lesion (LSIL) or inflammation were assigned to receive intra-vaginal, topical application of either Praneem tablet or placebo for 30 days excluding the days of menstrual period and were evaluated for persistence of HPV infection using HPV L1 consensus and HPV type 16-specific PCR as primary outcome.
  • RESULTS: One course of Praneem treatment resulted in elimination of HPV in 6 out of 10 (60%) cases.
  • A repeat treatment of four patients with persisting HPV infection resulted in clearance of HPV in two additional cases resulting in an overall 80% clearance of HPV 16 as against a spontaneous clearance of 10% (1/10) seen in the placebo arm.
  • CONCLUSION: Our results showed for the first time that a 30-day intra-vaginal application of the Praneem can result in elimination of HPV infection from the uterine cervix.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / drug therapy. Human papillomavirus 16. Papillomavirus Infections / drug therapy. Plant Extracts / administration & dosage. Quinine / administration & dosage. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Algorithms. Antiviral Agents / administration & dosage. Female. Humans. Middle Aged. Placebos. Risk Factors. Vaginal Creams, Foams, and Jellies. Young Adult

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Jun;12(6):485-90 [12814991.001]
  • [Cites] Eur J Gynaecol Oncol. 2003;24(2):147-50 [12701965.001]
  • [Cites] Curr Med Chem Anticancer Agents. 2005 Mar;5(2):149-6 [15777222.001]
  • [Cites] Indian J Exp Biol. 1996 Jul;34(7):698-701 [8979510.001]
  • [Cites] Trans R Soc Trop Med Hyg. 2009 Feb;103(2):167-72 [18990416.001]
  • [Cites] J Natl Cancer Inst. 1995 Sep 20;87(18):1365-71 [7658497.001]
  • [Cites] J Ethnopharmacol. 1997 Jan;55(2):133-9 [9032626.001]
  • [Cites] Immunol Cell Biol. 1997 Apr;75(2):190-2 [9107574.001]
  • [Cites] Chembiochem. 2004 Apr 2;5(4):408-21 [15185362.001]
  • [Cites] J Natl Cancer Inst. 2002 Nov 6;94(21):1604-13 [12419786.001]
  • [Cites] Nat Immunol. 2002 Feb;3(2):196-200 [11812998.001]
  • [Cites] Lancet. 2004 Nov 13-19;364(9447):1757-65 [15541448.001]
  • [Cites] N Engl J Med. 1999 Nov 25;341(22):1633-8 [10572150.001]
  • [Cites] Cancer Immunol Immunother. 2004 Jul;53(7):642-50 [14985860.001]
  • [Cites] Indian J Exp Biol. 1998 Nov;36(11):1151-3 [10085786.001]
  • [Cites] J Am Acad Dermatol. 1998 Feb;38(2 Pt 1):230-9 [9486679.001]
  • [Cites] N Engl J Med. 2002 Nov 21;347(21):1645-51 [12444178.001]
  • [Cites] N Engl J Med. 1998 Feb 12;338(7):423-8 [9459645.001]
  • [Cites] Trans R Soc Trop Med Hyg. 2005 Oct;99(10):769-74 [16084547.001]
  • [Cites] J Gen Virol. 1999 Feb;80 ( Pt 2):409-17 [10073701.001]
  • [Cites] Am J Reprod Immunol. 2000 Mar;43(3):144-51 [10735590.001]
  • [Cites] Nat Rev Cancer. 2002 May;2(5):342-50 [12044010.001]
  • [Cites] Indian J Med Res. 2006 Apr;123(4):547-52 [16783046.001]
  • [Cites] PLoS Pathog. 2006 Jul;2(7):e69 [16839203.001]
  • [Cites] Trans R Soc Trop Med Hyg. 2006 Dec;100(12):1164-7 [16750546.001]
  • [Cites] Int J Immunopharmacol. 1992 Oct;14 (7):1187-93 [1452404.001]
  • [Cites] Br J Cancer. 2006 Nov 6;95(9):1250-7 [17060942.001]
  • [Cites] J Med Virol. 1992 Apr;36(4):239-45 [1315836.001]
  • [Cites] Int J Cancer. 2005 Mar 1;113(6):951-60 [15514944.001]
  • (PMID = 19526249.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Placebos; 0 / Plant Extracts; 0 / Praneem; 0 / Vaginal Creams, Foams, and Jellies; A7V27PHC7A / Quinine
  •  go-up   go-down


13. Klumb EM, Araújo ML Jr, Jesus GR, Santos DB, Oliveira AV, Albuquerque EM, Macedo JM: Is higher prevalence of cervical intraepithelial neoplasia in women with lupus due to immunosuppression? J Clin Rheumatol; 2010 Jun;16(4):153-7
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is higher prevalence of cervical intraepithelial neoplasia in women with lupus due to immunosuppression?
  • In spite of previously observed higher incidence of cervical dysplasia among systemic lupus erythematosus (SLE) patients, few studies have considered the influence of classic risk factors and the use of immunosuppressors (IM).
  • OBJECTIVES: To study cervical dysplasia prevalence among SLE patients submitted or not to immunosuppression and to evaluate its association with classic risk factors.
  • RESULTS: The prevalence of atypical squamous cells of undetermined significance, low-grade and high-grade intraepithelial lesions were significantly increased in SLE patients (12.8%, 5.8%, and 3.5%, respectively) compared with controls (3.1%, 0.9%, and none, respectively, P = 0.0001), although they presented significantly fewer classic risk factors for CC.
  • Multivariate analysis showed that SLE women had a 7-fold higher prevalence of cervical dysplasia (OR: 7.23, 95% IC: 3.40-15.38) and an 11-fold higher prevalence of premalignant cervical dysplasia (OR: 11.36, 95% IC: 2.57-50.10) compared with controls.
  • SLE patients with long-term use of IM presented even higher prevalence of low-grade and high-grade intraepithelial lesions in comparison with those without long-term use of these agents (68.7% vs. 31.1%, P = 0.03).
  • [MeSH-major] Cervical Intraepithelial Neoplasia / immunology. Immunocompromised Host. Immunosuppressive Agents / adverse effects. Lupus Erythematosus, Systemic / complications. Lupus Erythematosus, Systemic / drug therapy. Uterine Cervical Neoplasms / immunology
  • [MeSH-minor] Adult. Brazil / epidemiology. Case-Control Studies. Cross-Sectional Studies. Female. Humans. Middle Aged. Odds Ratio. Prevalence. Time Factors. Vaginal Smears

  • Genetic Alliance. consumer health - Cervical Intraepithelial Neoplasia.
  • Genetic Alliance. consumer health - Lupus.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Lupus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Rheumatol. 2010 Oct;16(7):355 [20921856.001]
  • (PMID = 20407390.001).
  • [ISSN] 1536-7355
  • [Journal-full-title] Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases
  • [ISO-abbreviation] J Clin Rheumatol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


14. Sikorski M, Zrubek H: Long-term follow-up of patients treated with recombinant human interferon gamma for cervical intraepithelial neoplasia. Int J Gynaecol Obstet; 2003 Aug;82(2):179-85
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of patients treated with recombinant human interferon gamma for cervical intraepithelial neoplasia.
  • OBJECTIVES: The immediate results of interferon gamma (IFN-gamma) treatment in the management of cervical intraepithelial neoplasia (CIN) have been described.
  • However, little is known of the long-term results of this conservative treatment and we aimed to assess them.
  • METHODS: We conducted a 5-year follow-up of 13 women with either complete response to intracervical administration of 6,000,000 IU of IFN-gamma (remission from human papilloma virus-induced CIN occurred in nine cases) or partial response (a lower grade of CIN and/or HPV clearance was achieved in four cases).
  • We found three cases of relapse of stage 1 CIN (CIN I), for a recurrence rate of 33.3%, and three cases of complete remission in four subjects with initial diagnosis of partial response.
  • CONCLUSIONS: Immunomodulation therapy with IFN-gamma has a high long-term efficacy; however, it is inferior to that of surgery.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cervical Intraepithelial Neoplasia / drug therapy. Interferon-gamma / therapeutic use. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Colposcopes. Female. Follow-Up Studies. Humans. Middle Aged. Papanicolaou Test. Recombinant Proteins. Treatment Outcome. Vaginal Smears

  • Genetic Alliance. consumer health - Cervical Intraepithelial Neoplasia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12873779.001).
  • [ISSN] 0020-7292
  • [Journal-full-title] International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
  • [ISO-abbreviation] Int J Gynaecol Obstet
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Recombinant Proteins; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


15. Keefe KA, Tadir Y, Tromberg B, Berns M, Osann K, Hashad R, Monk BJ: Photodynamic therapy of high-grade cervical intraepithelial neoplasia with 5-aminolevulinic acid. Lasers Surg Med; 2002;31(4):289-93
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy of high-grade cervical intraepithelial neoplasia with 5-aminolevulinic acid.
  • BACKGROUND AND OBJECTIVES: To determine the safety and efficacy of 5-aminolevulinic acid (ALA) as a topically applied photosensitizer for photodynamic therapy (PDT) of cervical intraepithelial neoplasia (CIN).
  • RESULTS: Thirty-two women (80%) completed the study with 1 year of follow-up.
  • Toxicity was tolerable and only consisted of spotting, vaginal discharge, mild cramping, and vaginal warmth.
  • CONCLUSIONS: PDT at this light and ALA dose is well tolerated but has minimal activity in the treatment of CIN 2 and CIN 3.
  • [MeSH-major] Aminolevulinic Acid / therapeutic use. Cervical Intraepithelial Neoplasia / drug therapy. Photochemotherapy / adverse effects. Photosensitizing Agents / therapeutic use. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Humans. Outcome Assessment (Health Care). Severity of Illness Index. Time Factors

  • Genetic Alliance. consumer health - Cervical Intraepithelial Neoplasia.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley-Liss, Inc.
  • (PMID = 12355576.001).
  • [ISSN] 0196-8092
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1K23CA87558; United States / NCI NIH HHS / CA / CA-32248
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


16. García-López P, Coll M, Cervera E, Reyes-Vermot L, Torres MA, Abrego-Pérez G, Hernández-Pájaro AI, Castañeda-Hernandez G, Mohar-Betancourt A, Meneses A: The systemic absorption of etoposide after intravaginal administration in patients with cervical intraepithelial lesions associated with human papillomavirus infection. Pharm Res; 2006 Feb;23(2):378-83
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The systemic absorption of etoposide after intravaginal administration in patients with cervical intraepithelial lesions associated with human papillomavirus infection.
  • PURPOSE: The purpose of this study was to determine the systemic absorption and the release of etoposide in cervical tissue administered via a vaginal ovule to women diagnosed with cervical intraepithelial lesions associated with human papillomavirus (HPV).
  • METHODS: Fifteen women with low- and high-grade intraepithelial neoplasia confirmed by colposcopic test received a 50-mg intravaginal etoposide dose three times a week for 3 weeks.
  • At the end of the study period, paralleled with the last ovule administered, blood samples were collected over a period of 24 h, and in situ cervical samples were obtained at 3 and 10 h after drug administration.
  • Etoposide concentrations were determined in plasma and in in situ cervical samples using the high-performance liquid chromatography method with electrochemical detection.
  • RESULTS: Pharmacokinetic analyses of plasma data indicated low or lack of systemic exposure of etoposide after the vaginal administration.
  • CONCLUSIONS: The results of the study suggest that the etoposide administered as intravaginal ovule is safe and tolerable and apparently could be a suitable option in patients with cervical intraepithelial neoplasia.
  • Clinical results and the true impact on HPV infection and evolution of dysplasia need to be confirmed.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacokinetics. Etoposide / pharmacokinetics. Papillomavirus Infections / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Salud Publica Mex. 2003;45 Suppl 3:S326-39 [14746025.001]
  • [Cites] Infect Dis Obstet Gynecol. 1999;7(4):186-9 [10449266.001]
  • [Cites] Salud Publica Mex. 2004 Mar-Apr;46(2):169-85 [15176580.001]
  • [Cites] J Clin Oncol. 1994 Jul;12(7):1427-35 [8021734.001]
  • [Cites] Ginecol Obstet Mex. 2002 May;70:244-7 [12148464.001]
  • [Cites] J Natl Cancer Inst. 1994 Apr 6;86(7):539-43 [8133537.001]
  • [Cites] Gan To Kagaku Ryoho. 1998 Dec;25(14):2249-57 [9881082.001]
  • [Cites] Oncology. 2001;60(3):221-7 [11340373.001]
  • [Cites] J Clin Oncol. 1989 Sep;7(9):1333-40 [2549204.001]
  • [Cites] Cancer. 1996 Jun 1;77(11):2275-9 [8635095.001]
  • [Cites] Drugs. 1990 Mar;39(3):438-90 [2184009.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 2002 Sep;366(3):218-25 [12172704.001]
  • [Cites] Gan To Kagaku Ryoho. 1989 Sep;16(9):3279-82 [2782919.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6B):3733-6 [12552985.001]
  • [Cites] Gan To Kagaku Ryoho. 1998 Nov;25(13):2061-8 [9838908.001]
  • [Cites] J Biol Chem. 1984 Nov 10;259(21):13560-6 [6092381.001]
  • [Cites] J Cell Biochem. 2000 May;78(2):334-49 [10842327.001]
  • [Cites] Obstet Gynecol. 1985 Jun;65(6):781-4 [4000568.001]
  • [Cites] Arch Med Res. 1999 May-Jun;30(3):212-5 [10427872.001]
  • [Cites] Gynecol Oncol. 1998 Aug;70(2):263-6 [9740702.001]
  • [Cites] J Med Invest. 2002 Aug;49(3-4):124-33 [12323001.001]
  • [Cites] Salud Publica Mex. 2003;45 Suppl 3:S376-87 [14746031.001]
  • [Cites] J Natl Cancer Inst. 2000 May 3;92(9):690-8 [10793105.001]
  • [Cites] Nucleic Acids Res. 1987 Oct 26;15(20):8217-34 [3671082.001]
  • [Cites] Cancer. 1990 Nov 15;66(10):2155-61 [2171746.001]
  • [Cites] Int J Clin Pharmacol Ther. 1995 Apr;33(4):232-9 [7620694.001]
  • [Cites] Nihon Sanka Fujinka Gakkai Zasshi. 1992 Feb;44(2):208-14 [1545173.001]
  • [Cites] Obstet Gynecol. 1999 Dec;94(6):954-61 [10576182.001]
  • (PMID = 16388409.001).
  • [ISSN] 0724-8741
  • [Journal-full-title] Pharmaceutical research
  • [ISO-abbreviation] Pharm. Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Indicators and Reagents; 6PLQ3CP4P3 / Etoposide
  •  go-up   go-down


17. Tristram A, Fiander A: Clinical responses to Cidofovir applied topically to women with high grade vulval intraepithelial neoplasia. Gynecol Oncol; 2005 Dec;99(3):652-5
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical responses to Cidofovir applied topically to women with high grade vulval intraepithelial neoplasia.
  • It has previously been used in a number of clinical settings, including high grade intraepithelial disease in the cervix and low grade vulval disease.
  • This pilot study was set up to assess whether Cidofovir might be useful in treating high grade vulval intraepithelial neoplasia.
  • METHODS: Women with high grade non-cervical anogenital intraepithelial neoplasia were treated with a topical formulation of 1% Cidofovir in Unguentum Merck.
  • RESULTS: 12 women with high grade vulval, vaginal or perianal intraepithelial neoplasia were recruited, 10 of whom completed follow up.
  • Diseased tissue underwent ulceration in the majority of cases, with no effect seen on neighbouring normal skin.
  • CONCLUSION: These complete responses, in women with long standing disease, together with preservation of normal tissue, suggest that topical treatment with Cidofovir may have a place in the therapeutic armamentarium of high grade vulval intraepithelial neoplasia.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma in Situ / drug therapy. Cytosine / analogs & derivatives. Organophosphonates / administration & dosage. Vulvar Neoplasms / drug therapy
  • [MeSH-minor] Administration, Topical. Adult. Aged. Female. Humans. Middle Aged. Neoplasm Recurrence, Local / drug therapy

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16169066.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


18. van Seters M, Fons G, van Beurden M: Imiquimod in the treatment of multifocal vulvar intraepithelial neoplasia 2/3. Results of a pilot study. J Reprod Med; 2002 Sep;47(9):701-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imiquimod in the treatment of multifocal vulvar intraepithelial neoplasia 2/3. Results of a pilot study.
  • OBJECTIVE: To investigate the efficacy of topical treatment with imiquimod 5% cream, an immune response modifier, in patients with vulvar intraepithelial neoplasia (VIN) 2/3.
  • STUDY DESIGN: Fifteen women (aged 35-51) with histologically proven multifocal VIN 2/3 without invasion, were entered into a prospective, observational, pilot study.
  • Imiquimod 5% cream was applied by the patient to the vulvar lesions one to three times a week at night.
  • RESULTS: Four patients achieved CR (27%) and nine patients, PR (60%) after 6-34 weeks of treatment.
  • Two patients discontinued medication.
  • CR was reached after 6, 7, 11 and 30 weeks of treatment.
  • CONCLUSION: This pilot study showed the potential beneficial effect of imiquimod 5% cream in multifocal VIN 2/3.
  • In contrast to current surgical treatment, imiquimod focuses on the cause of VIN and preserves the anatomy and function of the vulva.
  • Therefore, imiquimod may prove to be the treatment of choice in multifocal, high grade VIN.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma in Situ / drug therapy. Vulvar Neoplasms / drug therapy
  • [MeSH-minor] Administration, Topical. Adult. Female. Humans. Middle Aged. Neoplasm Staging. Pilot Projects. Prospective Studies. Time Factors. Vaginal Creams, Foams, and Jellies

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12380448.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Vaginal Creams, Foams, and Jellies; 99011-02-6 / imiquimod
  •  go-up   go-down


19. Campagne G, Roca M, Martínez A: Successful treatment of a high-grade intraepithelial neoplasia with imiquimod, with vulvar pemphigus as a side effect. Eur J Obstet Gynecol Reprod Biol; 2003 Aug 15;109(2):224-7
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of a high-grade intraepithelial neoplasia with imiquimod, with vulvar pemphigus as a side effect.
  • Imiquimod modulates the immune response, and is a new approach for treatment of papillomavirus-associated lesions, although it has not been approved for the treatment of intraepithelial neoplasia.
  • We present a case of a patient treated with imiquimod on account of high-grade intraepithelial neoplasia in the vulva and other locations.
  • The posterior biopsies confirm the absence of lesions but show drug-induced pemphigus as a side effect.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / therapy. Genital Neoplasms, Female / therapy. Pemphigus / chemically induced. Vulvar Diseases / chemically induced
  • [MeSH-minor] Adult. Carcinoma in Situ / diagnosis. Carcinoma in Situ / therapy. Carcinoma in Situ / virology. Female. Humans. Papillomaviridae / drug effects. Papillomavirus Infections / chemically induced. Treatment Outcome. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / therapy. Uterine Cervical Neoplasms / virology. Vaginal Neoplasms / diagnosis. Vaginal Neoplasms / therapy. Vaginal Neoplasms / virology. Vulvar Neoplasms / diagnosis. Vulvar Neoplasms / therapy. Vulvar Neoplasms / virology

  • Genetic Alliance. consumer health - Pemphigus.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Pemphigus.
  • MedlinePlus Health Information. consumer health - Vulvar Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Obstet Gynecol Reprod Biol. 2004 Aug 10;115(2):242-3 [15262368.001]
  • (PMID = 12860347.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


20. Hefler L, Grimm C, Tempfer C, Reinthaller A: Treatment with vaginal progesterone in women with low-grade cervical dysplasia: a phase II trial. Anticancer Res; 2010 Apr;30(4):1257-61
Hazardous Substances Data Bank. PROGESTERONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment with vaginal progesterone in women with low-grade cervical dysplasia: a phase II trial.
  • BACKGROUND: The development of low-grade cervical dysplasia (CIN I) has been linked to a decrease of apoptosis and Langerhans cell (LC) count in the cervical epithelium and to an increase in the expression of various adhesion molecules.
  • We hypothesized that vaginal progesterone would increase the regression rate in women with CIN I.
  • MATERIALS AND METHODS: A non-randomized, open phase II trial with vaginal progesterone as treatment of CIN I was performed.
  • Forty women were treated with vaginal micronized progesterone at 400 mg daily for 10 days/month from menstrual cycle day 16-25 for 6 months.
  • RESULTS: The mean (standard deviation) age of women in the treatment and control groups was 32.0 (7.6) and 32.6 (8.5) years, respectively.
  • A total of 30% and 38.3% of CIN I regressed in the treatment and control group, respectively.
  • In a multivariate model, a higher number of children, a higher lifetime number of sexual partners, a lower age at first intercourse, non-use of condoms as contraception, current smoking, and treatment with vaginal progesterone were associated with a higher probability of having persistent or progressive CIN.
  • Current smoking and treatment with vaginal progesterone were associated with a higher probability of undergoing LLETZ.
  • CONCLUSION: Treatment with vaginal progesterone is associated with a lower rate of disease regression and a higher rate of surgical interventions in women with CIN I.
  • We suggest that vaginal progesterone treatment should not be applied in women with known dysplasia.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / drug therapy. Progesterone / administration & dosage. Progestins / administration & dosage. Uterine Cervical Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20530437.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Progestins; 0 / Suppositories; 4G7DS2Q64Y / Progesterone
  •  go-up   go-down


21. Sikorski M, Zrubek H: Recombinant human interferon gamma in the treatment of cervical intraepithelial neoplasia (CIN) associated with human papillomavirus (HPV) infection. Eur J Gynaecol Oncol; 2003;24(2):147-50
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recombinant human interferon gamma in the treatment of cervical intraepithelial neoplasia (CIN) associated with human papillomavirus (HPV) infection.
  • Human papillomavirus (HPV) proteins E6 & E7 are considered to be the constitutively expressed neoantigens in a vast majority of cervical squamous intraepithelial lesions and cancers.
  • In order to study this effect in vivo we undertook a trial in which 20 women with a definite diagnosis of cervical intraepithelial neoplasia (CIN) grade I or II with coexistent high-risk HPV infection (detected by the Hybrid Capture System) underwent four months observation followed by intracervical administration of INFgamma in cases without spontaneous regression (17 cases).
  • Human recombinant interferon gamma 1-b (Imukin) was administered intracervically four times in equal doses in two-day intervals to a total dose of 6,000,000 IU.
  • The results of therapy were verified by punch biopsy evaluation and HPV-DNA testing two months after completion, and revealed a complete response in nine women (complete regression of CIN and remission of HPV infection in 53% of treated cases) and partial response in four cases (lower grade of CIN or/and remission of HPV infection--23.5%).
  • The differences between spontaneous (before treatment) and treatment-related regressions were significant at p < 0.05.
  • We conclude that in selected cases (mainly young women who have not completed their procreation and are compliant with the therapy) a conservative approach to CIN management with intracervical IFNgamma injections seems to be a valuable method.
  • [MeSH-major] Antiviral Agents / therapeutic use. Cervical Intraepithelial Neoplasia / drug therapy. Interferon-gamma / therapeutic use. Papillomaviridae. Papillomavirus Infections / drug therapy. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Female. Humans. Middle Aged. Prospective Studies. Recombinant Proteins. Treatment Outcome. Vaginal Smears

  • Genetic Alliance. consumer health - Cervical Intraepithelial Neoplasia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12701965.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Recombinant Proteins; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


22. Caprara L, Monari F, De Bianchi PS, Amadori A, Bondi A: [ASCUS in screening]. Pathologica; 2001 Dec;93(6):645-50
Hazardous Substances Data Bank. PROGESTERONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The significance and use of the cytological diagnosis "atypical squamous cells of undetermined significance" (ASCUS) remain a major problem in cervical cancer screening.
  • The prevalence of diagnoses of low-grade squamous intraepithelial lesions (LG-SIL) decreased progressively with age while that of high-grade SIL was slightly higher between 30 and 39 years.
  • The observed peak reflects the prevalence of (1) cytological changes closely associated with perimenopausal age and at least compatible with the ASCUS diagnosis, and (2) cytological abnormalities induced by hormone replacement therapy.
  • [MeSH-major] Cervix Uteri / pathology. Mass Screening. Papanicolaou Test. Vaginal Smears
  • [MeSH-minor] Adult. Aged. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Cervical Intraepithelial Neoplasia / diagnosis. Cervical Intraepithelial Neoplasia / pathology. Epithelial Cells / drug effects. Epithelial Cells / ultrastructure. Estrogens / pharmacology. False Positive Reactions. Female. Hormone Replacement Therapy. Humans. Italy. Menopause. Middle Aged. Neoplastic Stem Cells / ultrastructure. Progesterone / pharmacology. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / pathology


23. van Hamont D, Bekkers RL, Massuger LF, Melchers WJ: Detection, management, and follow-up of pre-malignant cervical lesions and the role for human papillomavirus. Rev Med Virol; 2008 Mar-Apr;18(2):117-32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection, management, and follow-up of pre-malignant cervical lesions and the role for human papillomavirus.
  • High-grade cervical intraepithelial neoplasia (CIN) detected by cervical cytological screening is extensively visualised by colposcopy and successively treated by, for instance, large loop electro-surgical excision of the transformation zone.
  • HPV assessment, either DNA detection or HPV genotyping, could enhance the current cervical cancer screening programmes.
  • [MeSH-major] Papillomaviridae / classification. Papillomaviridae / isolation & purification. Papillomavirus Infections / diagnosis. Papillomavirus Infections / drug therapy. Precancerous Conditions / diagnosis. Precancerous Conditions / drug therapy
  • [MeSH-minor] Cervical Intraepithelial Neoplasia / diagnosis. Cervical Intraepithelial Neoplasia / drug therapy. Cervical Intraepithelial Neoplasia / virology. DNA, Viral / analysis. Electrosurgery. Female. Humans. Papillomavirus Vaccines. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / virology. Vaginal Smears

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18001004.001).
  • [ISSN] 1052-9276
  • [Journal-full-title] Reviews in medical virology
  • [ISO-abbreviation] Rev. Med. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Papillomavirus Vaccines
  • [Number-of-references] 125
  •  go-up   go-down


24. Joshi J, Affandi MZ, Amin P, Vaidya R, Shah R: Persistence of cytologic abnormality after treatment of bacterial, parasitic and fungal infections in older women with low grade squamous intraepithelial lesion. Acta Cytol; 2010 Mar-Apr;54(2):242-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persistence of cytologic abnormality after treatment of bacterial, parasitic and fungal infections in older women with low grade squamous intraepithelial lesion.
  • [MeSH-major] Anti-Infective Agents / therapeutic use. Cervical Intraepithelial Neoplasia / drug therapy. Uterine Cervical Dysplasia / drug therapy. Vaginal Smears
  • [MeSH-minor] Adult. Aged. Anti-Bacterial Agents / therapeutic use. Antifungal Agents / therapeutic use. Antiprotozoal Agents / therapeutic use. Female. Humans. Male. Middle Aged. Outcome Assessment (Health Care) / methods. Outcome Assessment (Health Care) / statistics & numerical data

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20391993.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anti-Infective Agents; 0 / Antifungal Agents; 0 / Antiprotozoal Agents
  •  go-up   go-down






Advertisement